LOGO
LOGO

Article Search

Discover the power of RTTNews website's advanced search page, designed for seamless Article retrieval by Company Name, Stock Symbol, and other criteria.
Stay updated with the Latest News on specific Companies, Financial Insights, and Market Trends. We Ensure you to get the most relevant information instantly.

Symbol  
Company  
Currency Symbol   eg (EUR/USD)
Keyword  
  • Wedbush Reiterates Spyre Therapeutics, Inc. (SYRE) At Outperform With $65 Price Target 1/13/2025 6:09:52 PM
  • Spyre Therapeutics Doses First Participants In Phase 1 Trials Of Novel Half-life Extended Anti-TL1A Antibodies 12/2/2024 8:18:55 AM
  • Wedbush Is Lowering Spyre Therapeutics, Inc. (SYRE) FY25 Estimate To -3.15 From -3.08 11/12/2024 10:10:15 AM
  • Wedbush Is Lowering Spyre Therapeutics, Inc. (SYRE) Q4 25 Estimate To -0.76 From -0.74 11/12/2024 10:10:04 AM
  • Wedbush Is Lowering Spyre Therapeutics, Inc. (SYRE) Q3 25 Estimate To -0.75 From -0.73 11/12/2024 10:09:53 AM
  • Wedbush Is Lowering Spyre Therapeutics, Inc. (SYRE) Q2 25 Estimate To -0.78 From -0.76 11/12/2024 10:09:41 AM
  • Wedbush Is Cutting Spyre Therapeutics, Inc. (SYRE) Q1 25 Estimate To -0.86 From -0.84 11/12/2024 10:09:24 AM
  • Spyre Therapeutics Announces Positive Interim Results From Phase 1 Trial Of SPY001 For IBD 11/12/2024 7:34:31 AM
  • Wedbush Reiterates Spyre Therapeutics, Inc. (SYRE) At Outperform With $45 Price Target 11/8/2024 8:17:03 PM
  • Wedbush Reiterates Spyre Therapeutics, Inc. (SYRE) At Outperform With $45 Price Target 10/14/2024 6:33:26 PM
  • Spyre Therapeutics Announces Grants Of Inducement Awards 10/4/2024 5:03:56 PM
  • Spyre Therapeutics Appoints Sheldon Sloan As Chief Medical Officer 10/1/2024 8:08:24 AM
Copyright © 2026 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service. About Us   |   Contact Us   |   Privacy   |   Sitemap